{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:37:45Z","timestamp":1793911065220,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020193","name":"Novartis Pharmaceuticals Australia Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["MRF1200067"],"award-info":[{"award-number":["MRF1200067"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2009670"],"award-info":[{"award-number":["GNT2009670"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijgc.2026.105600","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:42:14Z","timestamp":1791020534000},"page":"105600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PARAGON-II cohort C: a phase II basket study of letrozole plus ribociclib in hormone receptor\u2013positive, platinum-resistant, high-grade epithelial ovarian cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-9820","authenticated-orcid":false,"given":"Chee Khoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-3722","authenticated-orcid":false,"given":"Danka S.","family":"Zebic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-9767","authenticated-orcid":false,"given":"Rachel L.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeh C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8555-0161","authenticated-orcid":false,"given":"Katherine E.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-6603","authenticated-orcid":false,"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Baron-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7576-8565","authenticated-orcid":false,"given":"Lawrence","family":"Kasherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnesh","family":"Srivastav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Steer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Meniawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1274-2575","authenticated-orcid":false,"given":"Sandy","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7447-2728","authenticated-orcid":false,"given":"Leanna","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3689-5956","authenticated-orcid":false,"given":"Clare L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-1838","authenticated-orcid":false,"given":"Alison","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-795X","authenticated-orcid":false,"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.105600_bib1","series-title":"StatPearls","article-title":"Epithelial ovarian cancer","author":"Arora","year":"2026"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105600_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105600_bib3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.105600_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ijgc-2021-003142","article-title":"Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study","volume":"32","author":"Lee","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"10.1016\/j.ijgc.2026.105600_bib5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10496","key":"10.1016\/j.ijgc.2026.105600_bib6","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ijgc.2026.105600_bib7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ijgc.2026.105600_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102732","article-title":"Pembrolizumab VS placebo plus paclitaxel \u00b1 bevacizumab for platinum-resistant recurrent ovarian cancer: results from the PHASE 3 ENGOT-OV65\/KEYNOTE-B96 study","volume":"35","author":"Colombo","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.105600_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105600_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/0284186X.2018.1546061","article-title":"Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study","volume":"58","author":"Bagge","year":"2019","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.105600_bib11","doi-asserted-by":"crossref","first-page":"e910","DOI":"10.1093\/oncolo\/oyae093","article-title":"Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature","volume":"29","author":"Aubert","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ijgc.2026.105600_bib12","article-title":"NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer","volume":"4","author":"Network","year":"2026","journal-title":"Plymouth Meeting, PAVersion"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105600_bib13","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3802\/jgo.2019.30.e86","article-title":"Paragon (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression","volume":"30","author":"Kok","year":"2019","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105600_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/bjc.2016.435","article-title":"Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)","volume":"116","author":"Lindemann","year":"2017","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.105600_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105600_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","article-title":"The Strange case of CDK4\/6 inhibitors: mechanisms, resistance, and combination strategies","volume":"3","author":"Knudsen","year":"2017","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2026.105600_bib17","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105600_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cjp2.109","article-title":"Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study","volume":"4","author":"Rambau","year":"2018","journal-title":"J Pathol Clin Res"},{"issue":"10","key":"10.1016\/j.ijgc.2026.105600_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijgc.2026.105600_bib20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105600_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11136-017-1729-8","article-title":"Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer","volume":"27","author":"King","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijgc.2026.105600_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.02.025","article-title":"Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer","volume":"185","author":"Roncolato","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.105600_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2025.05.022","article-title":"A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)","volume":"198","author":"Damian","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105600_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105600_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO-25-01348","article-title":"Phase II trial of ribociclib plus letrozole in women with recurrent low-grade serous carcinoma of the ovary, Fallopian tube, or peritoneum: a GOG partners trial (GOG 3026)","volume":"44","author":"Slomovitz","year":"2026","journal-title":"J Clin Oncol"},{"issue":"7353","key":"10.1016\/j.ijgc.2026.105600_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"7553","key":"10.1016\/j.ijgc.2026.105600_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105600_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/cncr.34582","article-title":"CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an Ovarian Tumor Tissue Analysis consortium study","volume":"129","author":"Kang","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105600_bib29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cell.2022.12.036","article-title":"Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication","volume":"186","author":"Zeng","year":"2023","journal-title":"Cell"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.105600_bib30","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1200\/JCO.2025.43.16_suppl.5514","article-title":"Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)","volume":"43","author":"Damian","year":"2025","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2026.105600_bib31","doi-asserted-by":"crossref","first-page":"32848","DOI":"10.18632\/oncotarget.15858","article-title":"Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers","volume":"8","author":"Feng","year":"2017","journal-title":"Oncotarget"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2601131X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2601131X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:12:09Z","timestamp":1793909529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2601131X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S1048891X2601131X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105600","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARAGON-II cohort C: a phase II basket study of letrozole plus ribociclib in hormone receptor\u2013positive, platinum-resistant, high-grade epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"105600"}}